Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Delayed Immune Response to SARS-CoV-2 Explain Why More Men Die from COVID-19

By HospiMedica International staff writers
Posted on 10 Sep 2020
A study by researchers from the University of Washington (Seattle, Wash., USA) suggests that varying immune responses to SARS-CoV-2 due to age and sex could explain why COVID-19 infections tend to be more severe among older adults and males.

The SARS-CoV-2 virus causes more severe COVID-19 infections and higher mortality among elderly and male patients as compared to women, indicating that weaker immune responses may be contributing to the underlying poor clinical outcomes for these two demographics. More...
However, scientists have not yet been able to understand the mechanisms behind the increased death rate among these two patient populations caused by SARS-CoV-2.

The University of Washington researchers attempted to better understand the mechanisms behind the varied response of COVID-19 infected patients among different demographics by extracting and sequencing viral RNA from swabs collected from 430 COVID-19 positive cases and 54 negative controls. The researchers then went on to analyze their antiviral and immune responses across infection status, viral load, age and sex. They found that the immune cell responses were activated only three days after the start of infection, and also observed fluctuations in immune cell composition and function with viral loads, pointing to a dysfunctional antiviral response in males and the elderly. The findings of the study have significant implications for the development of immunomodulatory treatments for SARS-CoV-2

In their study published in the open access journal PLOS Biology, the authors wrote, "Collectively, our data demonstrate that host responses to SARS-CoV-2 are dependent on viral load and infection time with observed differences due to age and sex that may contribute to disease severity."

Related Links:
University of Washington


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.